Evidence first
Every claim our platform makes traces back to images and experiments.
About Anima
Giving AI the biology it's missing
Anima Biotech brings together cell biologists, chemists and AI engineers to make cellular biology something machines can see, test and learn from.
Our mission
Better, safer drugs, designed with real biology
Most AI drug discovery models learn from structures and sequences. They rarely see what a molecule does inside a living cell. We built BioGPU to change that, by turning high-content imaging into a runtime that AI agents can query and run experiments on.
We work with leading pharma partners and on our own programs to show that visual biology finds mechanisms that other approaches miss.
Milestones
- FoundedAnima Biotech starts with a focus on imaging mRNA biology in cells.
- First pharma partnershipA discovery collaboration with Lilly on mRNA-targeted small molecules.
- Growing alliancesCollaborations with Takeda and AbbVie broaden the platform.
- BioGPUThe platform becomes a cellular biology runtime for AI agents.
Mockup content: confirm milestone details and dates before publishing.
What drives us
Our values
Biology meets compute
Biologists and engineers work as one team, not as separate departments.
Partnership
We succeed when our partners' programs reach patients.
Leadership
The team
Yochi Slonim, M.Sc.
Co-founder & CEO, Board member
Iris Alroy, PhD
Co-founder & CSO
Avi Eliassaf
Chief Operating Officer
Generoso Ianniciello, M.Sc.
Chief Business Officer
Yossi Oulu, M.Sc.
VP, Software Development
Yuval Tsadik, MBA
VP of Finance
Rick Lufkin
VP, Administration
Yoni Sheinberger, PhD
VP of Discovery
Inbal Shapira Lots, PhD
VP of Data Science & AI
Boaz Inbal, PhD
VP of Chemistry
Moty Klepfish, PhD
VP of Therapeutic Areas
Initials stand in for headshots. Add photos to assets/img/team/.
Join us
We're hiring biologists, chemists and AI engineers.